Literature DB >> 22220518

Fine needle aspirate cell blocks are reliable for detection of hormone receptors and HER-2 by immunohistochemistry in breast carcinoma.

S P Bueno Angela1, R M Viero, C T Soares.   

Abstract

AIMS: To evaluate the reliability of fine needle aspirate cell blocks in the assessment of oestrogen receptor (ER), progesterone receptor (PR) and HER-2/neu proteins by immunohistochemistry in comparison with surgical specimens.
MATERIALS AND METHODS: This is a retrospective study of 62 cases of breast carcinoma diagnosed by fine needle aspiration cytology (FNAC) and confirmed using the surgical specimen. Immunohistochemical tests were performed to assess the presence of oestrogen receptor (ER), progesterone receptor (PR) and HER-2/neu proteins in cell blocks and the corresponding surgical specimens. The cell block method used alcohol prior to formalin fixation. Cases with 10% or more stained cells were considered positive for ER and PR. Positivity for HER-2/neu was assessed on a scale of 0-3+. The criterion for positivity was a score of 3+.
RESULTS: Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of the cell blocks in the investigation of ER, PR and HER-2/neu protein (3+) were (%): ER, 92.7, 85.7, 92.7, 85.7 and 90.3; PR, 92.7, 94.7, 97.4, 87.0 and 93.5; HER-2/neu, 70.0, 100.0, 100.0, 94.5 and 95.2. Discrepancies were seen in cell blocks in the 1+ and 2+ HER-2/neu staining scores: two of 12 cases scoring 2+ and one case of 26 scoring 1+ on cell blocks scored 3+ on surgical specimens. The correlation index between cell block and corresponding surgical specimen varied from 90% to 94%.
CONCLUSION: Cell blocks provide a useful method of assessing ER, PR and HER-2/neu, mainly for inoperable and recurrent cases, but consideration should be given to carrying out FISH analysis on 1+ as well as 2+ HER-2/neu results.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22220518     DOI: 10.1111/j.1365-2303.2011.00934.x

Source DB:  PubMed          Journal:  Cytopathology        ISSN: 0956-5507            Impact factor:   2.073


  7 in total

Review 1.  HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.

Authors:  Angela N Bartley; Mary Kay Washington; Christina B Ventura; Nofisat Ismaila; Carol Colasacco; Al B Benson; Alfredo Carrato; Margaret L Gulley; Dhanpat Jain; Sanjay Kakar; Helen J Mackay; Catherine Streutker; Laura Tang; Megan Troxell; Jaffer A Ajani
Journal:  Am J Clin Pathol       Date:  2016-11-14       Impact factor: 2.493

2.  Assessment of Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Status in Breast Carcinoma Using Thin-Prep Cytology Fine Needle Aspiration Cytology FISH Experience From China.

Authors:  Zhihui Zhang; Peng Yuan; Huiqin Guo; Linlin Zhao; Jianming Ying; Mingrong Wang; Huan Zhao; Qinjing Pan; Binghe Xu
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

3.  Hormone Receptors and Human Epidermal Growth Factor (HER2) Expression in Fine-Needle Aspirates from Metastatic Breast Carcinoma - Role in Patient Management.

Authors:  Issam M Francis; Rabeah Abbas Altemaimi; Bushra Al-Ayadhy; Preeta Alath; Mohammed Jaragh; Fatma Jasem Mothafar; Kusum Kapila
Journal:  J Cytol       Date:  2019 Apr-Jun       Impact factor: 1.000

4.  Evaluating Estrogen Receptor Immunohistochemistry on Cell Blocks From Breast Cancer Patients in a Low-Resource Setting.

Authors:  Asteria H Kimambo; Edda A Vuhahula; Amos R Mwakigonja; Britt-Marie Ljung; Li Zhang; Katherine Van Loon; Dianna L Ng
Journal:  Arch Pathol Lab Med       Date:  2021-07-01       Impact factor: 5.686

5.  HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens.

Authors:  Rieko Nishimura; Nami Okamoto; Masakazu Satou; Kenta Kojima; Shinichi Tanaka
Journal:  Diagn Cytopathol       Date:  2016-01-22       Impact factor: 1.582

6.  Bright-field HER2 dual in situ hybridization (DISH) assay on breast cancer cell blocks: a comparative study with histological sections.

Authors:  Rieko Nishimura; Nami Okamoto; Masakazu Satou; Kenta Kojima; Shinichi Tanaka; Natsumi Yamashita
Journal:  Breast Cancer       Date:  2016-01-08       Impact factor: 4.239

7.  Clinical significance of evaluating hormone receptor and HER2 protein using cell block against metastatic breast cancer: a multi-institutional study.

Authors:  Akira Matsui; Yuya Murata; Norikazu Masuda; Kiyoshi Mori; Masato Takahashi; Katsushige Yamashiro; Kenjirou Aogi; Shigeto Maeda; Masahiro Itou; Shinji Ozaki; Kazuya Kuraoka; Yasuyuki Satou; Shu Ichihara; Eriko Tokunaga; Kenichi Taguchi; Takanori Watanabe; Hiroyoshi Suzuki; Aiko Nagayama; Rieko Nishimura
Journal:  Oncotarget       Date:  2019-10-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.